Compare PRDO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | NVAX |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 1997 | 1996 |
| Metric | PRDO | NVAX |
|---|---|---|
| Price | $29.08 | $8.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.11 |
| AVG Volume (30 Days) | 621.8K | ★ 6.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | 10.50 | ★ 309.76 |
| EPS | ★ 2.31 | N/A |
| Revenue | $581,296,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $1.53 | N/A |
| Revenue Next Year | $1.86 | N/A |
| P/E Ratio | $12.56 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $26.24 | $6.20 |
| 52 Week High | $38.50 | $13.39 |
| Indicator | PRDO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 37.52 |
| Support Level | $26.24 | $7.81 |
| Resistance Level | $34.94 | $10.53 |
| Average True Range (ATR) | 1.34 | 0.76 |
| MACD | -0.11 | -0.16 |
| Stochastic Oscillator | 41.65 | 5.98 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.